Moderate Evidence
Research Overview
Alixorexton Research for Cataplexy
An overview of research and source records on Alixorexton in the context of cataplexy.
Research Summary
Orexin signaling normally prevents inappropriate muscle relaxation during wakefulness. By restoring OX2R activation, alixorexton reduced cataplexy episode frequency in Phase 2 trials. This addresses cataplexy through its root cause rather than downstream pathways.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.